Comparative Pharmacology
Head-to-head clinical analysis: PERGOLIDE MESYLATE versus PERMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PERGOLIDE MESYLATE versus PERMAX.
PERGOLIDE MESYLATE vs PERMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ergoline-derived dopamine D2 receptor agonist; also activates D1 and D3 receptors, and has antagonist activity at α2-adrenergic and 5-HT2B receptors.
Dopamine D1/D2 receptor agonist; also activates α2-adrenergic and serotonin receptors, reducing prolactin secretion.
0.05 mg orally once daily for first 2 days, then increase by 0.1-0.15 mg/day every 3 days over 12 days, then by 0.25 mg/day every 3 days until optimal response; usual therapeutic range 2-3 mg/day divided 3 times daily; maximum 5 mg/day.
Initial: 0.05 mg orally once daily; titrate by 0.05-0.1 mg/day every 2-3 days; usual therapeutic dose: 0.1-0.5 mg three times daily; maximum: 1.5 mg three times daily.
None Documented
None Documented
Terminal elimination half-life: 15-27 hours (mean 21 hours); clinically relevant for once-daily dosing
Terminal elimination half-life: 27 hours (range 24-30 hours) in healthy adults; significantly prolonged in renal impairment (up to 100+ hours in ESRD), requiring dose adjustment.
Renal: 50-60% as metabolites; Fecal: 40-50%; Biliary: minor (<5%)
Renal: ~50% unchanged drug; biliary/fecal: ~40% as metabolites and parent drug; total clearance approximates hepatic blood flow.
Category C
Category C
Dopamine Agonist
Dopamine Agonist